Impact of Supply Chain Management on Painkiller Availability and Patient Access to Pain Relief
Keywords:
The availability of painkillers, patient access, supply chain management, pharmaceutical supply chain, regulatory frameworks, logistical difficulties, cooperative solutions, moral considerations, healthcare stakeholders, patient-centric approach, technological advancements, personalized medicine, regulatory agility, policy reforms, sustainable practices, international partnerships, equitable access, human dignity, healthcare landscape.Abstract
In the context of healthcare, this essay examines the complex interactions between supply chain management, the availability of painkillers, and patient access. The availability of painkillers is a critical component of patient care since it directly affects people's quality of life, comfort, and general wellbeing. The analysis of the pharmaceutical supply chain's complexity kicks off the inquiry. The manufacture, distribution, legal and ethical frameworks, and logistical difficulties all play a part in the accessibility of painkillers. Any link in this network could be disrupted, causing shortages and impeding patients' access to necessary pain relief. The availability of painkillers is greatly influenced by regulatory requirements and compliance. The study examines how various international rules affect the pharmaceutical sector, emphasizing how regulatory measures might unintentionally protect patient safety while also causing supply chain disruptions. The need of temperature-controlled logistics and inventory management is emphasized as the logistical difficulties in the distribution of painkillers are also examined. The study examines how unequal access to healthcare infrastructure can result in disproportionate distribution of painkillers, which can have an adverse effect on patients in neglected areas. Collaboration becomes a significant enabler for providing patient-centric painkiller availability in response to these difficulties. Stakeholders from all areas of healthcare must collaborate to improve communication, develop cutting-edge technical solutions, and put sustainable practices into action in order to maintain a resilient supply chain. The article explores potential scenarios for the availability of painkillers in the future. Block chain, Internet of Things (IoT) gadgets, and personalized medicine are examples of technological advancements that have the potential to enhance supply chain transparency, traceability, and patient outcomes. Global partnerships, regulatory flexibility, and policy reforms are emphasized as crucial elements for adjusting to changing healthcare environments and quickly meeting patients' requirements. The paper highlights that ensuring patient access to pain management is not only a medical requirement but also a fundamental ethical necessity. Ethical issues underpin the entire exploration. Healthcare stakeholders are obligated to put the needs of patients first and fight for fair access to pain relief, guided by the values of beneficence, autonomy, fairness, and human dignity. An appeal for action is made in the paper's conclusion to all participants in the healthcare ecosystem. It is emphasized that crucial stages toward a patient-centric strategy include empowering patient voices, collaborative efforts, regulatory reforms, technological advances, and a dedication to sustainable practices. Stakeholders can support an environment in which compassion, equity, and the reduction of human suffering are valued in healthcare through preserving ethical norms and acknowledging the necessity of assuring painkiller availability.
In the context of healthcare, this essay examines the complex interactions between supply chain management, the availability of painkillers, and patient access. The availability of painkillers is a critical component of patient care since it directly affects people's quality of life, comfort, and general wellbeing. The analysis of the pharmaceutical supply chain's complexity kicks off the inquiry. The manufacture, distribution, legal and ethical frameworks, and logistical difficulties all play a part in the accessibility of painkillers. Any link in this network could be disrupted, causing shortages and impeding patients' access to necessary pain relief. The availability of painkillers is greatly influenced by regulatory requirements and compliance. The study examines how various international rules affect the pharmaceutical sector, emphasizing how regulatory measures might unintentionally protect patient safety while also causing supply chain disruptions. The need of temperature-controlled logistics and inventory management is emphasized as the logistical difficulties in the distribution of painkillers are also examined. The study examines how unequal access to healthcare infrastructure can result in disproportionate distribution of painkillers, which can have an adverse effect on patients in neglected areas. Collaboration becomes a significant enabler for providing patient-centric painkiller availability in response to these difficulties. Stakeholders from all areas of healthcare must collaborate to improve communication, develop cutting-edge technical solutions, and put sustainable practices into action in order to maintain a resilient supply chain. The article explores potential scenarios for the availability of painkillers in the future. Block chain, Internet of Things (IoT) gadgets, and personalized medicine are examples of technological advancements that have the potential to enhance supply chain transparency, traceability, and patient outcomes. Global partnerships, regulatory flexibility, and policy reforms are emphasized as crucial elements for adjusting to changing healthcare environments and quickly meeting patients' requirements. The paper highlights that ensuring patient access to pain management is not only a medical requirement but also a fundamental ethical necessity. Ethical issues underpin the entire exploration. Healthcare stakeholders are obligated to put the needs of patients first and fight for fair access to pain relief, guided by the values of beneficence, autonomy, fairness, and human dignity. An appeal for action is made in the paper's conclusion to all participants in the healthcare ecosystem. It is emphasized that crucial stages toward a patient-centric strategy include empowering patient voices, collaborative efforts, regulatory reforms, technological advances, and a dedication to sustainable practices. Stakeholders can support an environment in which compassion, equity, and the reduction of human suffering are valued in healthcare through preserving ethical norms and acknowledging the necessity of assuring painkiller availability.
References
REFERENCES
Garcia, A. M. (2013). State laws regulating prescribing of controlled substances: balancing the public health problems of chronic pain and prescription painkiller abuse and overdose. The Journal of Law, Medicine & Ethics, 41(1_suppl), 42-45.
Powell, D., Pacula, R. L., & Jacobson, M. (2018). Do medical marijuana laws reduce addictions and deaths related to pain killers?. Journal of health economics, 58, 29-42.
Sahebi-Fakhrabad, A., Sadeghi, A. H., & Handfield, R. (2023, February). Evaluating state-level prescription drug monitoring program (PDMP) and pill mill effects on opioid consumption in pharmaceutical supply chain. In Healthcare (Vol. 11, No. 3, p. 437). MDPI.
Yarbrough, C. R. (2018). Prescription drug monitoring programs produce a limited impact on painkiller prescribing in Medicare Part D. Health services research, 53(2), 671-689.
Brief, U. N. I. C. E. F. (2020). Mitigating the impacts of COVID-19 on menstrual health and hygiene.
Abbas, K., Afaq, M., Ahmed Khan, T., & Song, W. C. (2020). A blockchain and machine learning-based drug supply chain management and recommendation system for smart pharmaceutical industry. Electronics, 9(5), 852.
Twillman, R. K., Kirch, R., & Gilson, A. (2014). Efforts to control prescription drug abuse: why clinicians should be concerned and take action as essential advocates for rational policy. CA: a cancer journal for clinicians, 64(6), 369-376.
Carrigan, E. (2013). Painkillers: there's no such thing when pain persists. Issues, (102), 15-19.
Musse, I. (2020). Employment Shocks and Demand for Pain Medication. Available at SSRN 3646543.
Strulik, H. (2021). From pain patient to junkie: An economic theory of painkiller consumption and its impact on wellbeing and longevity. Journal of Health Economics, 76, 102432.
Talbot, J., Stuckey, R., Crawford, L., Weatherby, S., & Mullin, S. (2021). Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment–real world outcomes. The Journal of Headache and Pain, 22, 1-10.
Burry, L. D., Barletta, J. F., Williamson, D., Kanji, S., Maves, R. C., Dichter, J., ... & Erstad, B. L. (2020). It takes a village…: contending with drug shortages during disasters. Chest, 158(6), 2414-2424.
Meier, B. (2003). Pain killer: A" wonder" drug's trail of addiction and death. Rodale.
Fakhrabad, A. S., Sadeghi, A. H., & Handfield, R. (2022). Evaluating State-Level Prescription Drug Monitoring Program (PDMP) and Pill Mill Effects on Opioid Consumption in Pharmaceutical Supply Chain.
Lucas, P., Reiman, A., Earleywine, M., McGowan, S. K., Oleson, M., Coward, M. P., & Thomas, B. (2013). Cannabis as a substitute for alcohol and other drugs: A dispensary-based survey of substitution effect in Canadian medical cannabis patients. Addiction Research & Theory, 21(5), 435-442.
Blake, V. K. (2017). Engaging health insurers in the war on prescription painkillers. Harv. L. & Pol'y Rev., 11, 485.
Thomas, L., Lohman, D., & Amon, J. (2010). Access to pain treatment and palliative care: A human rights analysis. Temp. Int'l & Comp. LJ, 24, 365.
Kuehn, B. M. (2007). Opioid prescriptions soar. Jama, 297(3), 249-251.
Celsi, F., Staffa, P., Lamba, M., Castro, V., Chermetz, M., Orzan, E., ... & Barbi, E. (2022). Photobiomodulation for lowering pain after tonsillectomy: Low efficacy and a possible unexpected adverse effect. Life, 12(2), 202.
Yaroson, E. V., Breen, L., & Matthias, O. (2017). Disruptions, recovery strategies and the pharmaceutical supply chain; empirical evidence from first tier customers in the United Kingdom.
Rees, D. I., Sabia, J. J., Argys, L. M., Latshaw, J., & Dave, D. (2017). With a little help from my friends: the effects of naloxone access and good samaritan laws on opioid-related deaths (No. w23171). national Bureau of economic research.
Abuse, P. P. State Laws Regulating Prescribing of Controlled Substances.
Fraser, B. A., Powell, R. A., Mwangi-Powell, F. N., Namisango, E., Hannon, B., Zimmermann, C., & Rodin, G. (2017). Palliative care development in Africa: lessons from Uganda and Kenya. Journal of Global Oncology, 4, 1-10.
Jamal, A. (2023). Embracing Nature's Therapeutic Potential: Herbal Medicine. International Journal of Multidisciplinary Sciences and Arts, 2(1), 117-126.
Kunnukattil Shaji, N. (2021). Grappling with Morphine: A Local History of Painkiller Use in Kerala, India. Canadian Bulletin of Medical History, 38(S1), S118-S142.
Fincham, J. E. (2021). Negative consequences of the widespread and inappropriate easy access to purchasing prescription medications on the internet. American Health & Drug Benefits, 14(1), 22.
Yang, M., Chen, X., Bo, L., Lao, L., Chen, J., Yu, S., ... & Liang, F. (2017). Moxibustion for pain relief in patients with primary dysmenorrhea: a randomized controlled trial. PLoS One, 12(2), e0170952.
Busch, A. (2014). Lawmakers Seek Release Of Drug E-Labeling Reg; OMB Hears Opposing View. InsideHealthPolicy. com's FDA Week, 20(7), 1-12.
Reifler, L. M., Droz, D., Bailey, J. E., Schnoll, S. H., Fant, R., Dart, R. C., & Bucher Bartelson, B. (2012). Do prescription monitoring programs impact state trends in opioid abuse/misuse?. Pain medicine, 13(3), 434-442.
Weiner, S. G., Malek, S. K., & Price, C. N. (2017). The opioid crisis and its consequences. Transplantation, 101(4), 678.
New York (State). Legislature. Senate. Health Committee, & Hannon, K. (2012). The Prescription Drug Crisis in New York State: A comprehensive approach. Senate Standing Committee on Health.
Cleary, J., Powell, R. A., Munene, G., Mwangi-Powell, F. N., Luyirika, E., Kiyange, F., ... & Cherny, N. I. (2013). Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Africa: a report from the Global Opioid Policy Initiative (GOPI). Annals of Oncology, 24, xi14-xi23.
Oleszkiewicz, P., Krysinski, J., Religioni, U., & Merks, P. (2021, January). Access to medicines via non-pharmacy outlets in European countries—a review of regulations and the influence on the self-medication phenomenon. In Healthcare (Vol. 9, No. 2, p. 123). MDPI.
Stannard, C. (2018). Opioids for pain in Europe: differing problems and differing solutions. European Pain Management, 225.
Clark, D. J., & Schumacher, M. A. (2017). America’s opioid epidemic: supply and demand considerations. Anesthesia & Analgesia, 125(5), 1667-1674.
Lovelock, B., & Lovelock, K. (2018). “We had a ball… as long as you kept taking your painkillers” just how much tourism is there in medical tourism? Experiences of the patient tourist. Tourism Management, 69, 145-154.’
Carbone, L. (2011). Pain in laboratory animals: the ethical and regulatory imperatives. PLoS One, 6(9), e21578.
Jones, M. R., Viswanath, O., Peck, J., Kaye, A. D., Gill, J. S., & Simopoulos, T. T. (2018). A brief history of the opioid epidemic and strategies for pain medicine. Pain and therapy, 7, 13-21.
Beasley, S. (2013). Pharmacists. InsideHealthPolicy. com's FDA Week, 19(44), 5-6.
Sommerfeld, M., & Wilsford, D. (2013). The Politics of Pain: Explaining Variances in Opioid Availability.
